Crinetics is a pharmaceutical company that discovers, develops, and commercializes small molecule drugs targeting G-protein coupled receptors to treat endocrine diseases and endocrine-related tumors. The company's lead product is an oral somatostatin receptor agonist for acromegaly and other endocrine disorders, with a pipeline of over ten candidates addressing conditions including Cushing's syndrome, congenital adrenal hyperplasia, and neuroendocrine tumors; it generates revenue by retaining global commercial rights to its internally discovered product candidates and licensing them selectively to partners. Crinetics operates a specialized commercial organization to market its therapies to rare disease specialists and endocrinologists while outsourcing manufacturing to contract partners, relying on patent protection and regulatory exclusivity to differentiate its oral small-molecule approach from existing injectable peptide therapies.